Biliary Tract Cancers (BTCs) Treatment Market Snapshot (2023 to 2033)
The global Biliary Tract Cancers (BTCs) Treatment Market is expected to garner a market value of US$ 3.2 Billion in 2023 and is expected to accumulate a market value of US$ 4.74 Billion by registering a CAGR of 4% in the forecast period 2023 to 2033. The market for Biliary Tract Cancers (BTCs) Treatment registered a CAGR of 3% in the historical period 2018 to 2022.
The Biliary Tract Cancers (BTCs) Treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The Biliary Tract Cancers (BTCs) Treatment market offers a range of products and services for its effective management and treatments including medications such as chemotherapy, chemotherapy drugs such as gemcitabine and cisplatin, surgery, and radiation therapy.
Report Attribute
Details
Expected Market Value (2023)
US$ 3.2 Billion
Anticipated Forecast Value (2033)
US$ 4.74 Billion
Projected Growth Rate (2023 to 2033)
4% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Biliary Tract Cancers (BTCs) Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider, Future Market Insights- the market for Biliary Tract Cancers (BTCs) Treatment reflected a value of 3% during the historical period, 2018 to 2022. During this period, the demand for treatment for Biliary Tract Cancers (BTCs) increased, as it is a group of rare but aggressive cancers that originate in the biliary tract, which includes the bile ducts, gallbladder, and ampulla of Vater. The treatment of BTCs typically involves surgery, chemotherapy, and radiation therapy, depending on the stage and location of the cancer.
Moving forward, it is expected that the Biliary Tract Cancers (BTCs) Treatment market will continue to grow significantly in the coming years, driven by factors such as an increase in the incidence of BTCs, the development of new treatment options, and a growing demand for effective therapies.
Overall, the demand for Biliary Tract Cancers (BTCs) Treatment is expected to increase in the forecast period of 2023 to 2033, driven by a growing need for effective solutions to prevent and manage Biliary Tract Cancers (BTCs). In recent years, several new treatment options have emerged for BTCs, including targeted therapies and immunotherapies. Targeted therapies are drugs that specifically target the molecular pathways that are involved in the growth and spread of cancer cells. Immunotherapies, on the other hand, use the body's own immune system to fight cancer cells.
Furthermore, in the years to come, driven by a combination of factors such as an increase in the incidence of BTCs, the development of new treatment options, and a growing demand for effective therapies, the market for Biliary Tract Cancers (BTCs) Treatment is expected to register a CAGR of 4% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of the Biliary Tract Cancers (BTCs) Treatment Market?
Growing advancements in diagnostic and treatment options to push the market growth
The Biliary Tract Cancers (BTCs) Treatment Market is expected to experience significant growth in the coming years, driven by several factors. Firstly, the incidence of BTCs is increasing globally, particularly in developed countries such as the United States and European countries. This increase is partly due to the rise in risk factors such as obesity, diabetes, and chronic liver diseases, which are associated with the development of BTCs.
Additionally, there is a growing demand for effective treatment options for BTCs, given the poor prognosis associated with these cancers. This demand is driving the development of new drugs and therapies, including targeted therapies and immunotherapies. The aging population is also contributing to the growth of the BTCs treatment market. As people age, their risk of developing BTCs increases, leading to a higher demand for treatment options.
Furthermore, advancements in diagnostic techniques, such as imaging and biomarker testing, are improving the early detection of BTCs, which can lead to better outcomes and increased demand for treatment. Increasing investment in research and development by pharmaceutical and biotech companies is also contributing to the growth of the BTCs treatment market. These companies are developing new drugs and therapies that target specific molecular pathways involved in the development and progression of BTCs.
Overall, the combination of these factors is expected to drive significant growth in the BTCs treatment market in the coming years.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Biliary Tract Cancers (BTCs) Treatment Market?
Expensive Cost of Treatment to restrict Market Growth
One of the biggest challenges in managing Biliary Tract Cancers (BTCs) is the lack of awareness about the condition and its health consequences. Awareness of BTCs is relatively low among the general public and healthcare providers, which can delay diagnosis and treatment.
While there are several treatment options available for Biliary Tract Cancers (BTCs), there is still a need for more effective and innovative solutions. The cost of treatment for BTCs can be high, particularly for newer drugs and therapies. This can limit access to treatment, particularly in developing countries.
Furthermore, regulatory challenges can limit the development and approval of new drugs and therapies for BTCs, which can slow down progress in the field.
Region-Wise Insights
How is the Biliary Tract Cancers (BTCs) Treatment Market Turning Out in the South & East Asia Region?
Increasing Advancements in the Diagnostic Techniques Shaping Landscape for Biliary Tract Cancers (BTCs) Treatment in South & East Asia
The Biliary Tract Cancers (BTCs) Treatment Market in the South and East Asia region is growing, driven by several factors such as the increasing incidence of BTCs, growing awareness about the disease, and advancements in diagnostic techniques.
In South and East Asia, liver fluke infection is a common cause of BTCs, particularly in Thailand, Vietnam, and parts of China. As a result, these countries have a high incidence of BTCs, leading to a growing demand for effective treatment options.
In addition, there is a growing awareness about the disease in the region, which is leading to more frequent diagnoses and better access to treatment. Governments and healthcare organizations are also taking steps to improve the diagnosis and treatment of BTCs, which is helping to drive growth in the market. Advancements in diagnostic techniques, such as imaging and biomarker testing, are also improving the early detection of BTCs, leading to better outcomes and increased demand for treatment.
What are the Factors Boosting the Market for Biliary Tract Cancers (BTCs) Treatment in North America?
Increasing Focus on Technological advancements Shaping Landscape for Biliary Tract Cancers (BTCs) Treatment in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising incidence of BTCs in North America, which is driving the demand for effective treatment options. This is partly due to risk factors such as obesity, diabetes, and chronic liver diseases.
Additionally, North America has a well-developed healthcare infrastructure which is leading to improvements in imaging and biomarker testing enabling earlier detection of BTCs, leading to better outcomes and increased demand for treatment. Governments in North America are implementing initiatives to improve the detection and treatment of BTCs, which is driving demand for effective therapies.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
By Route of Administration, Which Segment is Likely to Account for a Significant Share?
Injectable segment to hold a significant share and push market growth
According to various reports and studies, the injectable segment is expected to grow due to the increasing prevalence of BTCs, which is driving demand for these drugs.
Furthermore, advancements in drug delivery technologies such as novel drug delivery systems, including drug-eluting stents, nanotechnology-based drug delivery, and implantable drug delivery systems, are also expected to boost the growth of the injectable segment in the BTCs treatment market.
Overall, the injectable segment is likely to account for a significant share of the BTCs treatment market due to its effectiveness in delivering many of the drugs used to treat the disease and the increasing demand for these drugs.
By Drug Class, Which Segment is Likely to Account for a Significant Share?
Durvalumab to take the lead and drive market growth
Durvalumab is likely to account for a significant share in the biliary tract cancers (BTCs) treatment market. Durvalumab is an immune checkpoint inhibitor that works by blocking the PD-L1 protein on cancer cells, which helps the immune system to recognize and attack the cancer cells.
In 2020, the US FDA approved Durvalumab in combination with chemotherapy as a first-line treatment for advanced or metastatic BTCs, making it the first immunotherapy-based treatment approved for this indication. This approval has significantly boosted the market share of Durvalumab in the BTCs treatment market.
Market Competition
Key players in the market include companies such as Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, and BeiGene, along with healthcare providers and technology companies among other global players.
In September 2022, Durvalumab (Imfinzi, AstraZeneca UK Limited) was granted approval by the Food and Drug Administration on September 2, 2022 for treating adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with gemcitabine and cisplatin. In the TOPAZ-1 (NCT03875235) trial, which was a randomized, double-blind, placebo-controlled, multiregional study, the efficacy of the treatment was evaluated. The trial enrolled 685 patients who had histologically confirmed locally advanced unresectable or metastatic BTC and who had not previously undergone systemic therapy for advanced disease.
The demographics of the trial showed that 56% were Asian, 37% were White, 2% were Black, and 4% were of other races, while 7% were Hispanic or Latino. In terms of gender, 50% were male and 50% were female, with a median age of 64 years (ranging from 20-85). 47% of the participants were 65 years or older. In the trial, 56% of patients had intrahepatic cholangiocarcinoma, 25% had gallbladder cancer, and 19% had extrahepatic cholangiocarcinoma.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 3.2 Billion
Market Value in 2033
US$ 4.74 Billion
Growth Rate
CAGR of 4% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Key Segments Profiled in the Biliary Tract Cancers (BTCs) Treatment Industry Survey
Drug Class:
Durvalumab
Zanidatamab
Ramucirumab
Route of Administration:
Inhalation
Intravenous
Intranasal
Subcutaneous
Oral
Parenteral
Molecule type:
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Small molecule
Stem Cell
Product Type:
Mono
Combination
Mono/Combination
Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Frequently Asked Questions
Which industry is the key consumer of Biliary Tract Cancers Treatment Market?
The primary consumer for Biliary Tract Cancers (BTCs) Treatment is the healthcare industry.
Who are the Key Biliary Tract Cancers Market Players?
Some of the key players in the Biliary Tract Cancers (BTCs) Treatment Market include AbbVie, Genentech, Johnson & Johnson, Novartis, and Pfizer.
What is Current Market Valuation?
The market is estimated to secure a valuation of US$ 3.2 billion in 2023.
How Big will the Biliary Tract Cancers Market by 2033?
The market is estimated to reach US$ 4.74 billion by 2033.
Which End-use Industry holds Lucrative Opportunities?
The oncology sector holds high revenue potential.
Table of Content
1. Executive Summary | Biliary Tract Cancers (BTCs) Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Durvalumab
5.3.2. Zanidatamab
5.3.3. Ramucirumab
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Inhalation
6.3.2. Intravenous
6.3.3. Intranasal
6.3.4. Subcutaneous
6.3.5. Oral
6.3.6. Parenteral
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Molecule Type
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Molecule Type , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Molecule Type , 2023 to 2033
7.3.1. Antibody
7.3.2. Antisense oligonucleotides
7.3.3. Immunotherapy
7.3.4. Monoclonal antibody
7.3.5. Peptides
7.3.6. Protein
7.3.7. Small molecule
7.3.8. Stem Cell
7.4. Y-o-Y Growth Trend Analysis By Molecule Type , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Molecule Type , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033
8.3.1. Mono
8.3.2. Combination
8.3.3. Mono/Combination
8.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Molecule Type
10.2.5. By Product Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Molecule Type
10.3.5. By Product Type
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Molecule Type
11.2.5. By Product Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Molecule Type
11.3.5. By Product Type
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Molecule Type
12.2.5. By Product Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Molecule Type
12.3.5. By Product Type
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Molecule Type
13.2.5. By Product Type
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Molecule Type
13.3.5. By Product Type
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Class
14.2.3. By Route of Administration
14.2.4. By Molecule Type
14.2.5. By Product Type
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By Molecule Type
14.3.5. By Product Type
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Drug Class
15.2.3. By Route of Administration
15.2.4. By Molecule Type
15.2.5. By Product Type
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Molecule Type
15.3.5. By Product Type
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Class
16.2.3. By Route of Administration
16.2.4. By Molecule Type
16.2.5. By Product Type
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Class
16.3.3. By Route of Administration
16.3.4. By Molecule Type
16.3.5. By Product Type
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Drug Class
17.1.2.2. By Route of Administration
17.1.2.3. By Molecule Type
17.1.2.4. By Product Type
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Drug Class
17.2.2.2. By Route of Administration
17.2.2.3. By Molecule Type
17.2.2.4. By Product Type
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Drug Class
17.3.2.2. By Route of Administration
17.3.2.3. By Molecule Type
17.3.2.4. By Product Type
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Drug Class
17.4.2.2. By Route of Administration
17.4.2.3. By Molecule Type
17.4.2.4. By Product Type
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Drug Class
17.5.2.2. By Route of Administration
17.5.2.3. By Molecule Type
17.5.2.4. By Product Type
17.6. United kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Drug Class
17.6.2.2. By Route of Administration
17.6.2.3. By Molecule Type
17.6.2.4. By Product Type
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Drug Class
17.7.2.2. By Route of Administration
17.7.2.3. By Molecule Type
17.7.2.4. By Product Type
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Drug Class
17.8.2.2. By Route of Administration
17.8.2.3. By Molecule Type
17.8.2.4. By Product Type
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Drug Class
17.9.2.2. By Route of Administration
17.9.2.3. By Molecule Type
17.9.2.4. By Product Type
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Drug Class
17.10.2.2. By Route of Administration
17.10.2.3. By Molecule Type
17.10.2.4. By Product Type
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Drug Class
17.11.2.2. By Route of Administration
17.11.2.3. By Molecule Type
17.11.2.4. By Product Type
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Drug Class
17.12.2.2. By Route of Administration
17.12.2.3. By Molecule Type
17.12.2.4. By Product Type
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Drug Class
17.13.2.2. By Route of Administration
17.13.2.3. By Molecule Type
17.13.2.4. By Product Type
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Drug Class
17.14.2.2. By Route of Administration
17.14.2.3. By Molecule Type
17.14.2.4. By Product Type
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Drug Class
17.15.2.2. By Route of Administration
17.15.2.3. By Molecule Type
17.15.2.4. By Product Type
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Drug Class
17.16.2.2. By Route of Administration
17.16.2.3. By Molecule Type
17.16.2.4. By Product Type
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Drug Class
17.17.2.2. By Route of Administration
17.17.2.3. By Molecule Type
17.17.2.4. By Product Type
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Drug Class
17.18.2.2. By Route of Administration
17.18.2.3. By Molecule Type
17.18.2.4. By Product Type
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Drug Class
17.19.2.2. By Route of Administration
17.19.2.3. By Molecule Type
17.19.2.4. By Product Type
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Drug Class
17.20.2.2. By Route of Administration
17.20.2.3. By Molecule Type
17.20.2.4. By Product Type
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Drug Class
17.21.2.2. By Route of Administration
17.21.2.3. By Molecule Type
17.21.2.4. By Product Type
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Class
18.3.3. By Route of Administration
18.3.4. By Molecule Type
18.3.5. By Product Type
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Incyte Corporation
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Loxo Oncology
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Bayer
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Roche
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Genentech
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. QED Therapeutics
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Agios Pharmaceuticals
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Servier Pharmaceuticals
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Merck Sharp & Dohme
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. AstraZeneca
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Taiho Oncology
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Delcath Systems
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. Eisai
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.14. TransThera Sciences (Nanjing)
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
19.1.15. Basilea Pharmaceutica
19.1.15.1. Overview
19.1.15.2. Product Portfolio
19.1.15.3. Profitability by Market Segments
19.1.15.4. Sales Footprint
19.1.15.5. Strategy Overview
19.1.15.5.1. Marketing Strategy
19.1.16. Zymeworks
19.1.16.1. Overview
19.1.16.2. Product Portfolio
19.1.16.3. Profitability by Market Segments
19.1.16.4. Sales Footprint
19.1.16.5. Strategy Overview
19.1.16.5.1. Marketing Strategy
19.1.17. BeiGene
19.1.17.1. Overview
19.1.17.2. Product Portfolio
19.1.17.3. Profitability by Market Segments
19.1.17.4. Sales Footprint
19.1.17.5. Strategy Overview
19.1.17.5.1. Marketing Strategy
20. Assumptions & Acronyms Used21. Research Methodology
